Compound-Marker Interactions

Testosterone enanthate stimulates erythropoiesis through EPO upregulation, raising haematocrit. Levels above 54% increase thrombotic risk and require intervention.

Testosterone aromatises to estradiol via the aromatase enzyme. Managing estradiol is central to TRT optimisation, with both excess and deficiency causing symptoms.

Testosterone enanthate stimulates red blood cell production through EPO upregulation and hepcidin suppression, raising haemoglobin by 1-2 g/dL on TRT doses. Haemoglobin rises in parallel with haematocrit and is a key marker for polycythemia monitoring.

All androgens suppress HDL cholesterol via hepatic lipase activation. Testosterone at TRT doses typically reduces HDL by 10-20%, while supraphysiological doses cause 20-40% reduction. The impact is less severe than with oral steroids or trenbolone.

Testosterone drives erythropoiesis, increasing iron demand for haemoglobin synthesis. Ferritin drops as iron stores are consumed, and repeated phlebotomy accelerates the decline into functional or absolute iron deficiency.

Testosterone suppresses hepcidin, increasing iron absorption and mobilisation. Serum iron initially rises, but chronic EPO-driven erythropoiesis and phlebotomy can eventually deplete circulating iron as stores are exhausted.

Testosterone suppresses hepcidin, increasing iron availability and raising transferrin saturation. In iron-replete men, saturation can exceed 45%, triggering hemochromatosis workup. In men undergoing phlebotomy, saturation may drop as iron stores are depleted.

Testosterone enanthate increases DHT through 5-alpha reductase conversion. The magnitude depends on dose and delivery method, with implications for hair loss, prostate health, and acne.

Exogenous testosterone and all anabolic-androgenic steroids suppress hepatic SHBG production. SHBG drops within 1-2 weeks of starting TRT, increasing the free testosterone fraction. The degree of suppression is dose-dependent and more aggressive with oral 17-alpha-alkylated steroids.

Exogenous testosterone suppresses LH to undetectable levels via negative feedback on the hypothalamic-pituitary-gonadal axis. This is universal at all TRT and supraphysiological doses and is the primary mechanism of TRT-induced infertility.

Testosterone enanthate raises serum creatinine via increased muscle mass and modest RAAS activation. The rise is usually 5 to 15 percent above baseline on TRT doses and can mask subclinical kidney injury when interpreted with creatinine alone.

Trenbolone is one of the most lipid-toxic anabolic steroids, suppressing HDL cholesterol by 50-70% even at moderate doses. This dramatically increases cardiovascular risk.

Trenbolone raises serum creatinine through increased muscle mass (higher creatine turnover) and possible direct renal tubular effects. Cystatin C is a more reliable marker for assessing true kidney function (GFR) on trenbolone.

Trenbolone elevates prolactin through progestogenic activity at pituitary lactotroph cells. Elevated prolactin can independently suppress LH, worsen gynecomastia risk, and impair sexual function, making it a critical marker to monitor during and after trenbolone use.

Trenbolone acetate stimulates erythropoiesis through potent androgen receptor activation without aromatisation to oestrogen. The absence of oestrogen-mediated plasma volume expansion creates a disproportionately elevated haematocrit relative to total blood volume, worsening blood viscosity.

Trenbolone does not aromatize, so it does not directly raise estradiol. However, standard immunoassay E2 tests produce falsely elevated readings due to antibody cross-reactivity with trenbolone metabolites. LC-MS/MS testing is required for accurate estradiol measurement on trenbolone.

Trenbolone is not 17-alpha alkylated, so direct hepatotoxicity is uncommon. However, one biopsy-confirmed case of cholestatic hepatitis from injectable trenbolone enanthate exists. AST/ALT elevation on tren is usually from muscle damage, not liver injury. GGT is the marker that distinguishes the two.

Trenbolone suppresses thyroxine-binding globulin (TBG) in the liver, lowering total T3 and T4 on blood tests. Free thyroid hormones and TSH typically remain normal. This is a lab artifact from TBG suppression, not true hypothyroidism. Do not start T3 supplementation based on low total T3 on trenbolone.

Trenbolone binds the mineralocorticoid receptor as a 19-nor agonist, driving sodium retention and potassium loss through the same receptor aldosterone uses. Combined with an ARB or ACE inhibitor, this creates an unusual but real hyperkalaemia risk if dosing changes around the cycle.

Nandrolone decanoate (Deca-Durabolin) increases prolactin through progesterone receptor agonism and modulation of dopamine pathways. Elevated prolactin causes sexual dysfunction, gynecomastia, and mood disturbances. Cabergoline is the first-line treatment.

Nandrolone decanoate (Deca-Durabolin) has the most favourable lipid safety profile of commonly used anabolic steroids. At moderate doses, HDL impact is minimal to modest, making it a preferred injectable for athletes prioritising cardiovascular harm reduction.

Nandrolone decanoate profoundly suppresses LH through dual androgen receptor and progesterone receptor-mediated negative feedback at the hypothalamus and pituitary. Suppression is deeper and more prolonged than with testosterone alone, with recovery often requiring months after the last injection.

Nandrolone decanoate (Deca-Durabolin) raises haematocrit through EPO stimulation and hepcidin suppression. Its erythropoietic effect is moderate relative to boldenone and high-dose testosterone, but it potentiates exogenous EPO and compounds erythropoiesis when stacked with other androgens.

Nandrolone aromatizes to estradiol at approximately 20% the rate of testosterone. The primary estrogenic concern on nandrolone is not direct aromatization but SHBG suppression amplifying free estradiol. Crashing E2 with an AI to fix sexual dysfunction on nandrolone is a common and harmful mistake.

Nandrolone binds progesterone receptors (it is a progestin) but does NOT raise serum progesterone levels. The community confusion between 'progestogenic activity' and 'elevated progesterone' is widespread. Serum progesterone testing is not useful on nandrolone. Prolactin is the actionable marker.

Nandrolone suppresses hepatic SHBG synthesis despite having very low SHBG binding affinity itself. Lower SHBG increases the free (bioavailable) fraction of both testosterone and estradiol. This means total hormone levels can appear normal while free hormone activity is substantially elevated.

CJC-1295 without DAC (modified GRF 1-29) is a short-acting GHRH analog that primes the pituitary for pulsatile GH release. Alone it modestly elevates IGF-1; paired with ipamorelin it amplifies the GH pulse to produce IGF-1 increases of 20-60% above baseline.

CJC-1295 no-DAC produces brief, pulsatile GH release that transiently elevates glucose in the post-injection window. Between pulses, insulin sensitivity recovers fully. At standard doses and injection frequencies, fasting glucose typically remains within the normal range.

CJC-1295 no-DAC's pulsatile GH pattern preserves insulin sensitivity between pulses. Fasting insulin and HOMA-IR are expected to remain stable at standard doses, in contrast to MK-677, which produces sustained GH elevation and meaningful insulin resistance.

CJC-1295 no-DAC acts exclusively on the GHRH receptor on pituitary somatotrophs. It does not activate the hypothalamic-pituitary-adrenal (HPA) axis and does not elevate ACTH or cortisol. This distinguishes GHRH analogs from some GHRPs like GHRP-6, GHRP-2, and hexarelin, which do raise cortisol.

CJC-1295 no-DAC does not affect prolactin. GHRH receptor activation on pituitary somatotrophs has no mechanism to stimulate lactotroph prolactin secretion. This is in contrast to GHRP-6 and other non-selective ghrelin receptor agonists.

GH-axis activation through GHRH analogs tends to preserve or modestly improve HDL and the total cholesterol to HDL ratio. Tesamorelin Phase 3 data (Falutz 2010) showed a 7.2% improvement in cholesterol to HDL ratio across 806 patients. CJC-1295 no-DAC, as a related GHRH analog, is expected to share this neutral to favourable lipid profile.

Ipamorelin is a selective GHRP that stimulates pulsatile GH release, producing dose-dependent IGF-1 elevation with a cleaner side-effect profile than other GH secretagogues. It does not affect cortisol, ACTH, prolactin, or gonadotropins.

Ipamorelin's pulsatile GH release pattern produces minimal impact on fasting glucose, distinguishing it sharply from MK-677 and exogenous GH. At standard bodybuilding doses, clinically significant glucose elevation is uncommon.

Ipamorelin's pulsatile, selective GH release leaves fasting insulin and HOMA-IR essentially unchanged at standard doses. It is the most insulin-friendly GH secretagogue, with no ghrelin-receptor-mediated pancreatic effects and no sustained GH elevation.

Ipamorelin does not elevate cortisol or ACTH, even at doses 200 times the effective GH-releasing dose. This cortisol selectivity is one of its defining advantages over older GHRPs and is the primary reason ipamorelin displaced GHRP-6 and hexarelin in performance peptide use.

Ipamorelin does not elevate prolactin. Raun et al. (1998) confirmed no prolactin change at 200 times the effective GH dose. This selectivity over GHRP-6, which raises prolactin via non-selective ghrelin receptor activation, is why ipamorelin became the dominant GHRP for bodybuilding use.

Ipamorelin can produce rare, transient TSH and free T4 changes through GH-mediated upregulation of type 1 deiodinase. The incidence is substantially lower than sermorelin's documented 6.5% subclinical hypothyroidism rate. Baseline and periodic thyroid monitoring is advisable on long-term protocols.

Tesamorelin is the only FDA-approved GHRH analog and produces dose-dependent IGF-1 elevation. The NEJM trial documented an 81% IGF-1 increase at 2 mg/day, with a favourable metabolic profile compared to other GH secretagogues.

Tesamorelin is the only GH secretagogue with documented triglyceride-lowering effects. The NEJM trial showed a 50 mg/dL reduction in triglycerides at 2 mg/day, along with improvements in total cholesterol-to-HDL ratio.

Tesamorelin is the only GHRH analog with controlled glucose data in over 800 patients across 52 weeks. The pooled Phase 3 trials showed no clinically meaningful change in fasting glucose, distinguishing it sharply from exogenous GH and MK-677, both of which raise fasting glucose dose-dependently.

Tesamorelin maintained HbA1c neutrality over 52 weeks in 806 Phase 3 patients in responders, with non-responders showing modest drift (+0.2-0.3%). The FDA label flags a small but real signal: 5% of treated patients crossed HbA1c 6.5% versus 1% on placebo, which is why baseline and quarterly monitoring is required.

Tesamorelin preserves insulin sensitivity by design. The Stanley 2011 hyperinsulinaemic-euglycaemic clamp in healthy men showed insulin-stimulated glucose uptake unchanged (p=0.61) on 2 mg/day for 2 weeks. This is the strongest mechanistic evidence that pulsatile GHRH stimulation does not impair peripheral insulin sensitivity, in contrast to continuous GH exposure.

Tesamorelin reduces hepatic fat fraction by 37% relative (-4.1% absolute) and normalises liver fat (<5% HFF) in 35% of patients with NAFLD over 12 months (Stanley 2019 Lancet HIV, PMID 31611038). ALT and AST track downward as hepatic steatosis improves. This is the strongest non-VAT story for tesamorelin and is particularly relevant for TRT users with oral 17-alpha-alkylated compound history.

Growth hormone is a counter-regulatory hormone to insulin, promoting gluconeogenesis and insulin resistance. Chronic use can elevate fasting glucose and HbA1c, potentially leading to type 2 diabetes.

Growth hormone increases the peripheral conversion of T4 to T3 by upregulating type 1 deiodinase. Free T3 levels rise while free T4 may decline. This interaction is clinically relevant when GH is combined with exogenous T3.

Exogenous growth hormone directly stimulates hepatic IGF-1 production, raising circulating levels in a dose-dependent manner. IGF-1 is the primary biomarker used to gauge GH activity, and sustained supraphysiological levels carry risks including organ enlargement and potential cancer promotion.

Growth hormone induces chronic insulin resistance that elevates average blood glucose over time, which is reflected in glycated haemoglobin (HbA1c). HbA1c is a more reliable indicator of GH-related metabolic harm than single fasting glucose readings because it captures cumulative glucose exposure over 2-3 months.

Growth hormone induces peripheral insulin resistance, forcing pancreatic beta cells to secrete more insulin to maintain glucose homeostasis. Fasting insulin rises before fasting glucose does, making it the earliest detectable warning sign of GH-related metabolic disruption.

MK-677 is a ghrelin mimetic that stimulates endogenous GH secretion, producing sustained 24-hour GH elevation rather than the normal pulsatile pattern. This continuous GH exposure drives persistent insulin resistance and glucose elevation through the same mechanisms as exogenous GH, with the added metabolic effects of ghrelin receptor activation.

MK-677's continuous GH stimulation creates sustained free fatty acid elevation that drives persistent compensatory hyperinsulinemia. Fasting insulin and HOMA-IR rise as pancreatic beta cells work harder to maintain glucose homeostasis, making fasting insulin the earliest warning signal of MK-677-related metabolic stress.

MK-677 stimulates sustained GH secretion via ghrelin receptor activation, producing dose-dependent IGF-1 elevation that persists throughout the 24-hour dosing interval. Unlike pulsatile GH secretagogues, MK-677's continuous GH stimulation drives IGF-1 into the upper physiological or supraphysiological range.

MK-677 raises HbA1c through sustained GH-mediated insulin resistance and elevated fasting glucose. The Nass et al. (2008) two-year RCT documented a 0.2% HbA1c increase compared to placebo, confirming a clinically measurable long-term glucose impact.

MK-677 drives sodium and water retention via GH-induced activation of the epithelial sodium channel (ENaC) in the renal collecting duct. The fluid retention is the most common reason users discontinue MK-677 in the first month.

Oxandrolone (Anavar) is the mildest oral anabolic steroid for hepatotoxicity. ALT typically rises 1.5-3x the upper limit of normal. It remains 17-alpha-alkylated but is used at lower doses and has a more favourable safety profile than other oral steroids.

Oxandrolone (Anavar) suppresses HDL via the same 17-alpha-alkylated hepatic lipase mechanism as stanozolol, but with moderate rather than severe effect. Despite its reputation as a 'mild' oral, oxandrolone is not lipid-neutral and produces clinically significant HDL reduction at bodybuilding doses.

Oxandrolone is one of the most aggressive SHBG suppressors in the AAS catalog. At 10 to 20 mg/day, female users routinely see SHBG drop 70 to 90 percent from baseline. The downstream effect is a disproportionate spike in free testosterone that quantifies virilization risk weeks before physical changes appear.

Oxandrolone is structurally a DHT derivative and elevates dihydrotestosterone activity directly via AR agonism in DHT-sensitive tissues. Finasteride and dutasteride do not block this effect because oxandrolone bypasses 5-alpha-reductase entirely. DHT-driven changes (scalp hair loss, body hair growth, sebaceous activation, vocal fold thickening, clitoral hypertrophy) are partially or fully irreversible.

Free testosterone on oxandrolone rises 4 to 15 fold above baseline in women at 10 to 20 mg/day, primarily driven by SHBG suppression rather than total testosterone elevation. This is the single most useful marker for quantifying virilization exposure and the one most likely to be misread if you only check total T.

Retatrutide is a triple agonist (GLP-1, GIP, glucagon) that lowers fasting and post-prandial glucose through glucose-dependent insulin secretion, glucagon suppression at the islet level, and delayed gastric emptying. In Phase 2 T2D trials, up to 82 percent of participants reached HbA1c below 6.5 percent by week 36 at 12mg.

Retatrutide produces the largest HbA1c reductions documented in the incretin class, up to 2.02 percentage points at 12mg over 36 weeks in T2D patients (Rosenstock 2023). Up to 82 percent of T2D participants reached HbA1c below 6.5 percent.

Retatrutide produces dramatic triglyceride reductions, up to 40.6 percent at 12mg in Phase 2 obesity trials. The mechanism combines reduced hepatic VLDL secretion, weight loss-driven adipose remodelling, and the glucagon arm's enhancement of fatty acid oxidation.

Retatrutide produces dramatic long-term ALT improvement through hepatic fat clearance (about 82 percent liver fat reduction in MASLD substudy, Sanyal 2024). Short-term, rapid fat mobilisation can transiently bump ALT in the first 4 to 12 weeks. The trajectory is variable depending on phase.

Asymptomatic lipase elevations are common on retatrutide, mirroring the GLP-1 class effect. Phase 2 reported 1 case of acute pancreatitis at 12mg. Pooled GLP-1 class meta-analysis (Wen 2025) shows pancreatitis RR 1.44 (95 percent CI 1.09 to 1.89), attenuating in subgroups using concomitant antidiabetic medication.

IGF-1 LR3 is injectable IGF-1 itself, modified to resist its binding proteins, so it raises bioactive IGF-1 activity directly rather than through the pituitary. Standard IGF-1 immunoassays may partly cross-react with it, so an on-cycle serum IGF-1 reading is hard to interpret.

IGF-1 LR3 lowers blood glucose by acting like insulin: it drives GLUT4 transporters to the muscle cell surface and pulls glucose out of the blood. Because the free peptide stays active for many hours, the hypoglycaemia risk is prolonged, and it is harder to self-correct than insulin hypoglycaemia.

IGF-1 LR3 suppresses your own insulin output because the body senses the insulin-like IGF-1 signal and the pancreas backs off. This makes a fasting insulin or HOMA-IR drawn on cycle deceptively low, masking the insulin resistance that chronic use actually drives.

HbA1c is the slow, honest counterweight to the deceptive on-cycle insulin numbers. Acute IGF-1 LR3 lowers glucose, but sustained supraphysiological IGF-1 drives insulin resistance, and a rising HbA1c over a quarter is the signal that the chronic metabolic cost is real.

Boldenone undecylenate (Equipoise) is considered the most disproportionately erythropoietic anabolic steroid per unit of androgenic activity. Its long-acting undecylenate ester creates a sustained EPO stimulus that drives haematocrit higher than testosterone at comparable androgenic doses.

Boldenone undecylenate drives significant haemoglobin elevation through sustained EPO stimulation, typically producing greater haemoglobin increases than testosterone at comparable androgenic doses. Values above 18.5 g/dL are common in users running extended boldenone cycles.

Boldenone (Equipoise) suppresses HDL through a dual pathway: direct androgenic hepatic lipase upregulation and indirect estradiol lowering from its aromatase-competing metabolite. The reputation of EQ as lipid-mild is partially misleading, as the estradiol-lowering effect creates a second independent HDL-suppressive mechanism.

Clomiphene citrate blocks estrogen receptors at the pituitary, removing negative feedback and stimulating LH release. This is the primary mechanism behind its use in post-cycle therapy and treatment of male hypogonadism.

Clomiphene acts as an estrogen agonist at the liver, directly stimulating hepatic SHBG production. This can mask testosterone recovery during PCT by binding free testosterone even as total testosterone levels normalize.

Clomiphene blocks estrogen receptors but does not reduce circulating estradiol levels. Estradiol often rises during clomiphene therapy because increased LH stimulates testosterone production, which aromatizes to estradiol.

Enclomiphene is the pure estrogen-antagonist isomer of clomiphene. By blocking estrogen receptors at the hypothalamus and pituitary, it removes negative feedback and causes a sustained, dose-dependent rise in endogenous LH without the estrogenic side effects of the zuclomiphene component in racemic clomiphene.

Enclomiphene raises FSH through the same pituitary SERM mechanism that elevates LH. The FSH response is what makes enclomiphene and other SERMs uniquely valuable for fertility: FSH drives spermatogenesis via Sertoli cells, an effect HCG cannot replicate.

Enclomiphene raises testosterone by stimulating endogenous LH production, which drives Leydig cell steroidogenesis. In hypogonadal men, enclomiphene raised testosterone comparably to testosterone gel while preserving spermatogenesis, something exogenous testosterone cannot do.

HCG mimics LH by binding the same receptor on Leydig cells, stimulating testosterone production. However, exogenous HCG suppresses endogenous LH through negative feedback, as the resulting testosterone rise signals the pituitary to reduce its own LH output.

HCG stimulates testicular Leydig cell aromatase, causing a disproportionate rise in estradiol relative to testosterone. At fertility-range doses, estradiol can peak at more than four times baseline within 24 hours, making E2 monitoring essential during HCG use.

HCG mimics LH at testicular Leydig cells, stimulating intratesticular testosterone production. The primary goal is maintaining intratesticular testosterone for spermatogenesis rather than raising serum testosterone, and the optimal dose is the lowest that preserves intratesticular levels.

MOTS-C is a mitochondrial-derived peptide that activates AMPK, the same energy-sensing pathway targeted by metformin and triggered by exercise. In animal models it lowers fasting glucose by driving insulin-independent glucose uptake into skeletal muscle. Human evidence is observational, and no completed trial has confirmed the effect in healthy athletes.

Fasting insulin is the most sensitive marker of MOTS-C's proposed mechanism. By activating AMPK and improving insulin-independent glucose uptake, MOTS-C should let the body clear glucose with less insulin, lowering fasting insulin and HOMA-IR. The effect is well-documented in mice and observationally linked in humans, but not yet proven in a controlled trial.

HbA1c reflects average blood glucose over roughly 90 days. If MOTS-C lowers glucose and improves insulin sensitivity as animal models suggest, HbA1c should hold steady or drift down over a full quarter. It is a slow, confirmatory marker rather than an early signal, and the human evidence behind any change is observational.

Oxymetholone (Anadrol) is one of the most hepatotoxic oral anabolic steroids. ALT can rise 5-20x the upper limit of normal, with peliosis hepatis and cholestatic jaundice being documented risks at prolonged high doses.

Oxymetholone (Anadrol) produces severe HDL suppression alongside extreme hepatotoxicity, creating one of the most atherogenic lipid profiles of any commonly used anabolic steroid. Case reports document HDL below 20 mg/dL during typical bodybuilding doses.

Oxymetholone (Anadrol) is the only anabolic steroid with an FDA approval specifically for treating anaemia caused by deficient red blood cell production. At therapeutic doses it substantially raises haemoglobin, but at bodybuilding doses (50-150 mg/day) this erythropoietic effect compounds with direct haematological toxicity and hepatotoxicity.

Stanozolol (Winstrol) is a 17-alpha-alkylated oral steroid with moderate hepatotoxicity. ALT typically rises 2-4x the upper limit of normal. Stanozolol is notable for having a worse impact on lipids than on the liver.

Stanozolol is the most lipid-destructive anabolic steroid documented in controlled trials, suppressing HDL by 33-70% and crashing HDL2 (the most protective subfraction) by up to 71% at doses as low as 6 mg/day.

Stanozolol enhances platelet aggregation through androgen receptor-mediated upregulation of platelet surface receptors and intracellular signalling pathways. Unlike most AAS, stanozolol's main haematological risk is on the coagulation axis rather than haematocrit elevation.

Anastrozole is a potent aromatase inhibitor that reduces estradiol by 70-85%. It is used to manage estrogen-related side effects on testosterone therapy, but over-use can crash estradiol to dangerously low levels.

Anastrozole suppresses HDL by inhibiting aromatase and reducing estradiol, which normally restrains hepatic lipase activity. Lower estradiol accelerates HDL catabolism independently of the direct androgenic pathway, adding a second HDL-suppressive mechanism on top of whatever testosterone is already doing.

BPC-157 is a synthetic pentadecapeptide with broad anti-inflammatory activity in animal models, acting through TNF-alpha suppression, IL-10 upregulation, and VEGF-a/ERK1/2 pathway modulation. Human data on hs-CRP specifically are anecdotal, but the preclinical inflammatory signal is consistent.

BPC-157 is hepatoprotective in rat models (Sikiric 1993) but has zero human RCT data showing ALT change. In healthy users, expect ALT to stay at baseline. Claims of protection against AAS hepatotoxicity are theoretical.

Halotestin (fluoxymesterone) is a very hepatotoxic 17-alpha-alkylated oral steroid. ALT typically rises 5-15x the upper limit of normal. It is used only briefly before competition for its potent androgenic and aggression-enhancing effects.

Halotestin may produce the single worst lipid profile of any commonly used AAS. As an extremely potent, non-aromatising, fluorinated 17-alpha-alkylated oral, it delivers maximum hepatic androgenic stimulation with zero estrogenic counterbalance and prolonged hepatic exposure due to fluorine-enhanced metabolic stability.

Methandrostenolone (Dianabol) is a 17-alpha-alkylated oral anabolic steroid that causes dose-dependent hepatotoxicity. ALT typically rises 2-5x the upper limit of normal during use, reflecting hepatocellular stress.

Methandrostenolone (Dianabol) suppresses HDL significantly as a 17-alpha-alkylated oral steroid, but its heavy aromatisation to estradiol provides partial mitigation compared to non-aromatising orals. Net effect is still significant HDL suppression of 30-50% at typical doses.

Semaglutide is a GLP-1 receptor agonist that reduces HbA1c by 1.0-1.8% through enhanced insulin secretion, suppressed glucagon, and delayed gastric emptying. It is increasingly used in bodybuilding contexts for fat loss and metabolic optimization.

Semaglutide reduces ALT by 10-30% over 3-6 months through reduction of hepatic steatosis (fatty liver). This is a beneficial effect, making semaglutide one of the few PEDs that improves rather than worsens liver markers.

Superdrol (methyldrostanolone) is one of the most hepatotoxic oral anabolic steroids. ALT can rise 10-30x the upper limit of normal within 2-3 weeks. Cholestatic jaundice is a well-documented risk even at standard doses.

Superdrol produces some of the most severe HDL suppression documented in bodybuilding, routinely crashing HDL to single digits within 2-4 weeks. As a non-aromatising 17-alpha-alkylated oral, it combines maximum first-pass hepatic androgenic loading with zero estrogenic counterbalance.

Exemestane is a suicidal (irreversible) aromatase inhibitor that reduces estradiol by 85-95%. Unlike anastrozole, it permanently inactivates aromatase enzymes, making it harder to titrate but offering a more favourable lipid profile.

GHK-Cu delivers 316mcg of elemental copper per 2mg dose, or ~17.7mg cumulative over an 8-week daily cycle. Copper and iron compete metabolically, and ferritin is both an iron storage marker and an acute-phase reactant. Direction is unpredictable; track with a full iron panel.

GLOW does not move albumin pharmacologically. Albumin is a substrate-availability check: low albumin means inadequate protein status to support the collagen synthesis GHK-Cu is supposed to drive. Address protein intake before starting.

Gonadorelin is synthetic GnRH that stimulates pulsatile LH and FSH release from the anterior pituitary. It maintains the entire HPG signalling cascade, offering a physiologically elegant alternative to HCG with less estradiol elevation and no Leydig cell desensitisation.

Sermorelin carries a documented 6.5% incidence of subclinical hypothyroidism per its FDA prescribing information. GH stimulation accelerates T4-to-T3 conversion, potentially depleting T4 and triggering compensatory TSH elevation.

SS-31 reduces mitochondrial reactive oxygen species by protecting cardiolipin, which in animal and ex-vivo models lowers downstream inflammatory signaling. Whether that translates to a measurable drop in high-sensitivity CRP in humans is unproven: no human trial has reported hs-CRP as an SS-31 endpoint. Treat any change as suggestive, not confirmatory.

Exogenous T3 (liothyronine/Cytomel) suppresses TSH through negative feedback on the hypothalamic-pituitary-thyroid axis. TSH can drop to near-zero during use. Recovery of endogenous thyroid function after discontinuation typically takes weeks to months.

TB-500 (thymosin beta-4) is a naturally occurring peptide with documented anti-inflammatory and anti-fibrotic activity. Phase 2 trial data show improvements in chronic wound inflammation; preclinical data demonstrate IL-6 and TNF-alpha suppression.